A Phase III Randomized Clinical Trial of a 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination, Preservative-Free Ophthalmic Solution vs. 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination in Patients with Controlled Primary Open-Angle Glaucoma

INTRODUCTION: The aim of this prospective crossover study was to evaluate the non-inferiority of PRO-122 (a preservative-free fixed combination) compared with 0.5% timolol + 0.2% brimonidine + 2.0% dorzolamide fixed combination (KOF) by evaluating its efficacy, tolerability and safety in subjects wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gómez-Aguayo, Francisco, Paczka, José A., Leñero-Córdova, Rubén, Jiménez-Román, Jesús, Davila-Villarreal, Jaime, Hartleben, Curt, Baiza-Durán, Leopoldo, Olvera-Montaño, Oscar, García-Velez, Francisco, Muñoz-Villegas, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997590/
https://www.ncbi.nlm.nih.gov/pubmed/29680880
http://dx.doi.org/10.1007/s40123-018-0128-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997590/
https://www.ncbi.nlm.nih.gov/pubmed/29680880
http://dx.doi.org/10.1007/s40123-018-0128-8

Ejemplares similares